Triheptanoin use for severe neonatal cardiomyopathy secondary to mitochondrial trifunctional protein deficiency: a first report
Mitochondrial trifunctional protein deficiency is a long-chain fatty acid disorder that may include manifestations of severe cardiomyopathy and arrhythmias. The pathophysiology for the severe presentation is unclear but is an indicator for worse outcomes. Triheptanoin, a synthetic medium chain triglyceride, has been reported to reverse cardiomyopathy in some individuals, but there is limited literature in severe cases. We describe a neonatal onset of severe disease whose clinical course was not improved despite mechanical support and triheptanoin.
Authors
- Giles J. Peek (ORCID: https://orcid.org/0000-0002-1313-6498)
- Jeffrey Phillip Jacobs (ORCID: https://orcid.org/0000-0002-9916-929X)
- Megan Boothe
- Anna McGuinness
- Mark S. Bleiweis (ORCID: https://orcid.org/0000-0002-1818-0009)
- Michael A. Brock (ORCID: https://orcid.org/0000-0002-0607-5930)
- Haley Blanchette
- Dipankar Gupta (ORCID: https://orcid.org/0000-0003-0143-7143)
- John‐Anthony Coppola (ORCID: https://orcid.org/0009-0009-4291-4373)
- Yun-Hom Yau
Institutions
- University of Florida (US)
Publication Details
- Journal
- Cardiology in the Young
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1017/s1047951124026386
- Citations
- 2
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.64